Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Kadam, D. Gothi, J. Joshi (Mumbai, Delhi, India). Osteoporosis, sarcopenia and pulmonary hypertension in relation to GOLD classification vs BODE index in COPD. Eur Respir J 2013; 42: Suppl. 57, 4182

Member's Comments

No comment yet.

Related content which might interest you: Associations between muscle wasting and BODE index in chronic obstructive pulmonary disease Source: International Congress 2014 – The assessment of comorbidities Year: 2014 NT-proBNP in assessment of pulmonary hypertension in COPD patients Source: Annual Congress 2013 –COPD treatment Year: 2013 Obesity and impairments in chronic obstruction pulmonary disease (COPD) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Co-morbidities and pulmonary arterial hypertension (PAH) in COPD patients Source: International Congress 2016 – Comorbidities and exacerbations in COPD Year: 2016 Pulmonary hypertension and COPD: Clinical assessment and biomarkers Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II Year: 2013 Study of inflammatory markers and BODE index in patients with chronic obstructive pulmonary disease Source: International Congress 2016 – Systemic biomarkers Year: 2016 The prevalence and characteristics of pulmonary hypertension in severe COPD Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Comorbidities and body mass index in subjects with chronic obstructive pulmonary disease Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 Acute and chronic effects of PDE5-Is on SpO2 in patients with COPD associated pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Anemia in patients with chronic obstructive pulmonary disease - Association with comorbidities Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases Year: 2016 Clinical Impact of Gensini score in chronic obstructive pulmonary disease (COPD) Source: International Congress 2016 – Monitoring comorbidities Year: 2016 The modified BODE index: validation with mortality in COPD Source: Eur Respir J 2008; 32: 1269-1274 Year: 2008 Chronic obstructive pulmonary disease and comorbidities Source: International Congress 2015 – Risk factors and co-morbidities in asthma and COPD Year: 2015 Characteristics of pulmonary function of COPD with and without arterial pulmonary hypertension Source: International Congress 2014 – Comorbidities Year: 2014 Pulmonary hypertension (PH) in chronic obstructive pulmonary disease (COPD): Preliminary data of a longitudinal survey Source: International Congress 2014 – Clinical presentations Year: 2014 Evidence of renal and pulmonary endothelial dysfunction in chronic obstructive pulmonary disease (COPD) Source: International Congress 2016 – New signalling pathways in COPD Year: 2016 Pulmonary rehabilitation and the BODE index in COPD Source: Eur Respir J 2005; 26: 630-636 Year: 2005 Mortality in COPD: role of comorbidities Source: Eur Respir J 2006; 28: 1245-1257 Year: 2006 Clinical factors linked with coronary artery disease in chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – Non inflammatory monitoring of airway diseases Year: 2014 Nutritional status in chronic obstructive pulmonary disease Source: International Congress 2014 – Comorbidities Year: 2014